Biotech Values

[DewDiligence]

Clinical / Regulatory / Litigation Calendar

[Please keep entries up to date! See updating procedure at the end of this post.]

NOTE: ANYONE MAY UPDATE THIS FILE


Edits: GTCB (Merrimack results at EULAR in June 07); YMI (3rd Tesmilifene data look in Feb 07).


ACHN – See GILD

ADLR – Approvable letter for Entereg issued 11/6/06 requesting safety data due in 2Q07.

AGIX – ARISE data at ACC March 24-27, 2007.

AMGN – Vectibix PACCE non-registrational trial in 1st-line CRC (Avastin+FOLFOX+/-Vectibix) RR Jan 07 (at quarterly CC); PACCE PFS 2Q07. Vectibix final OS from ‘408’ study: any day (low chance of hitting endpoint).

ANDS – ANA975 for HCV placed on hold 6/26/06 due to preclinical safety issue; human trials expected to resume in 2H07 following additional animal tox.

ANDS – ANA380 in HBV: phase-2 to begin in 2Q07.

ANOR / AOM.TO – pivotal AMD3100 results any day.

ASPM – Interim data from BRITE trial in depression: scientific conference in 2Q07.

BMY – Plavix trial begins 1/22/07.

BMY – Erbitux: see IMCL.

BOMSF -reporting pivotal MBP8298 results 2 years roughly

CEPH – Nuvigil for EDS approvable letter received 4/30/06; on 12/7/06, FDA said it was still studying one case of suspected SJS in Sparlon data set.

CLSC - Two phase 3 Trials 1600-2000 patients to complete in calendar Q4 with public " top line data" on results anticipated for calendar Q1 07. This is a 10 week trial.

COLY – Actilon for HCV: 1) SVR data for 20 continuing patients (out of a total of 74 patients) in the phase-1b relapsed-responder trial 1H07. (12-week data for this trial were reported Apr 2006: #msg-10881211.) 2) Some 12-week interim data from the lead Actilon trial, the phase-2 for null responders, any day.

CONR: see JNJ.

COR – CX717 completed toxicology data: Jan 2007. (FDA clinical hold was lifted 10/9/06.) Go/no-go decision on CX-717: Feb/Mar 2007.

CORT – Phase-3 trials of Corlux for psychotic major depression: ‘06’ trial results any day. (The first phase-3 trial called ’07’ reported failed results on 8/25/06; the 2nd phase-3 trial called ‘09’ reported failed results 9/29/06).

CRME - IV RSD1235 NDA refiled, FDA decision likely 4th qtr/07.

CYT.TO - Initiated pivotal A-fib trial Oct/06. Results timing, will update when company provides timeline.

CYPB – Phase-3 Milnacipran in fibromyalgia, second phase-3 results: mid 2007 (#msg-9132392).

DDSS (formerly LBPFF) – Response to and appeal of Tramadol approvable letter submitted 12/20/06.

DNA – Avastin in breast cancer: FDA requested additional data confirmation on 9/11/06; resubmission by DNA pending.

DNDN – Provenge BLA: priority-review determination by 1/12/07; advisory panel expected in March 2007; PDUFA date mid-May 2007 (assuming priority review).

DNDN – 9902b study: enrollment complete in 2007; interim data look 1H08.

FRX - Milnacipran in fibromyalgia: see CYPB.

GILD – Viread for HBV: phase-3 results 4Q07, NDA (if successful) 1H08.

GILD – GS9132 for HCV (with ACHN): phase-1/2 results 1Q07.

GILD – GS9190 for HCV: start phase-1 any day.

GPCB – Satraplatin SPARC trial: final overall survival: fall 2007. (The trial hit the primary PFS endpoint on 9/24/06; interim OS look announced on 6/8/06 failed to meet threshold for unblinding.)

GTCB – ATryn EU launch for HD: June, 2007.

GTCB – ATryn DIC program in EU: start of ph-2 (by Leo Pharma) any day.

GTCB – ATryn ph-3 for HD in U.S.: complete enrollment 1H07, submit BLA 2H07.

GTCB – Merrimack MM-093 phase-2b in RA, phase-2 in psoriasis to be presented at EULAR in June 2007.

GTOP – Final MyVax results Dec 07.

IDIX – Tyzeka for HBV action date in EU, China: early 2007 (approved by FDA 10/25/06).

IDIX – Tyzeka phase-3 in decompensated liver disease: enrollment complete in 1Q07 (75% complete as of 9/27/06).

IDIX – NM283+ribavirin drug-interaction study: 36-day efficacy data 1Q07; 12-week safety data late 1Q07 or 2Q07.

IMCL – (See #msg-9218093 for selected Erbitux trials):
1) CRSYTAL trial in first-line CRC hit its PFS endpoint (announced 1/10/07); full data release at ASCO in June, 2007.
2) Erbitux in NSCLC. OS in 1st-line FLEX study: 2H07.
3) Erbitux in pancreatic cancer, SWOG trial: 1Q07.

ISA.TO - Begin European/Cdn pivotal psoriasis trials this qtr, begin U.S. pivotal psoriasis 07, complete enrollment in renal Phase IIb & also interim renal data 1st qtr 07.

ITMN – Ph-1 data for ITMN-191: 1H07

JNJ: CoStar (CONR) data from U.S. pivotal trial: March 2007 at ACC

LBPFF – see DDSS

Merrimack: see GTCB

MS.TO - Complete enrollment in pivotal Secondary Progressive MS trial this year, possible interim results 2007, trial results in 2008.

Novocell – see SRDX

NRMX, NRM.TO – North American Alzhemed trial complete Jan 07, results to follow. European Alzhemed trial complete 1H08 (?). Kiacta (Fibrillex) received an approvable letter on 8/11/06.

NRPH – NRP104 in pediatric ADHD: approvable letter 10/6/06; full approval pending DEA scheduling.

NVS – Galvus PDUFA date late Feb 2007.

NVS – Tekturna PDUFA date mid Mar 2007.

NVS – Tifacogin: enrollment complete 1H07 (#msg-15157973).

PHRM – See GPCB.

PPHM - Bavituximab phase 1B HCV; four doses monotherapy over 14 days, followed for 12 weeks post-therapy, in previous non-responders/relapsers. Patient enrollment completed Oct 24, trial results due 1Q 07.

RPRX
All due end of March 2007
1) Phase II final results for Proellex in endometriosis
1) Phase II/III final results for Proellex in uterine fibroids
2) Phase III final results for Androxal

SGP – Ph-2 data for SCH 503034 in HCV: 2H07

SNY – Acomplia PDUFA date: 4/26/07.

SNY – Plavix litigation: trial begins 1/22/07.

Speedel – See NVS.

SPPI – See GPCB.

SRDX - Novocell phase-1/2 trial in type-1 diabetes: late summer 2007 (enrollment complete 8/30/06).

TH.TO -Begin confirmatory TH9507 HIV Associated Lipodystropy trial 1st qtr/07

VRTX – PROVE-1/PROVE-2/PROVE-3 timetable: see #msg-12267294

YMI – Tesmilifene phase-3: results of 3rd data look to be reported in Feb 2007.

YMI – AeroLEF final results any day (interim results announced on 9/27/06 failed to meet threshold).

--
Procedure For Updating Clinical-Trials List

When adding or modifying entries, please follow these steps:

1. Copy the complete text from the old list. You can find a pointer to this list in the iBox at the top of the main message-board screen.

2. Make your additions or modifications, inserting any new items in alphabetical order.

3. Post the updated text in a new message in reply to the message with the old list.